Last checked at 22 Jan 2015 08:32
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Immupharma Share News (IMM)
IMM Share
Price
IMM Share
News
IMM Share
Chat
IMM Share
Trades8
IMM
Live RNS
IMM Share
Charts
IMM Level 2
Console
IMM Live
Share Price
IMM Broker
Ratings
IMM Directors
Deals
IMM Financial
Diary
IMM
Fundamentals
IMM Short
Positions
IMM
Media
Immupharma Information
Share Price Information for Immupharma (IMM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.30
Bid:
2.16
Ask:
2.30
Change:
-0.09 (-3.88%)
Spread:
0.14 (6.481%)
Open:
2.30
High:
2.30
Low:
2.30
Prev. Close:
2.32
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Immupharma to make 'blockbuster' lupus treatment available
Fri, 07th Sep 2018 08:10
(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.The MAP will see as many as 500 sufferers of the condition gain access to Lupuzor for a minimum of two years, allowing the company to continue collecting data on the treatment after it missed its primary endpoint in a late stage study earlier this year.Tim McCarthy, chairman of ImmuPharma, said: "In the medium-term, we remain focused on achieving the full regulatory approval of Lupuzor which we believe has the potential to be a ground-breaking drug for Lupus patients and in turn has blockbuster potential in commercial terms."The AIM-traded company also reported that its Nucant cancer treatment has yielded "promising results" in two phase I safety and dose-finding studies and a licence agreement for the treatment is expected to be signed with oncology specialist Incanthera.This would likely see Incanthera pay an upfront licence fee of £1.0m in shares and cover all of the development costs for the Nucant programme, with future commercial revenues shared equally.Finally, the company confirmed its decision to sell its Ureka subsidiary, divesting the Bordeaux-based business while retaining an interest in case its treatments receive future commercial success."The board has been focused on delivering a business strategy which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, resources and know-how. We believe that the strategy outlined today provides the most effective route to create shareholder value going forward."ImmuPharma's shares were down 0.86% at 20.10p at 0850 BST.
More News
21 Oct 2014 11:16
Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial
Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per
Read more21 Oct 2014 11:00
5 Oct 2014 13:32
Sunday share tips: BG Group, Genel Energy, Palace Capital
Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I
Read more16 Jun 2014 10:52
ImmuPharma Granted New US Patent For Nucant Cancer Treatments
LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate
Read more16 Jun 2014 08:14
Immupharma gains new patents for Nucant treatments
Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane
Read more21 May 2014 13:14
ImmuPharma's patient approach disappoints
Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t
Read more21 May 2014 11:45
ImmuPharma Losses Widen As It Accelerates Research And Development
LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million
Read more27 Sep 2013 12:23
27 Sep 2013 10:30
ImmuPharma reports half-year loss
ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it
Read more13 Aug 2013 09:17
Immupharma progresses with cancer treatment trials
ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p
Read more